Palvella Therapeutics在预设关键次要终点及全部四项次要疗效终点均达到统计学显著性(所有P值均小于0.001)

美股速递
Feb 24

生物制药公司Palvella Therapeutics宣布,其临床研究在预设的关键次要终点上取得了统计学显著性结果,P值小于0.001。此外,该研究还成功在所有四项次要疗效终点上均显示出统计学显著性,所有P值同样低于0.001。

这一系列积极数据进一步验证了该公司在研疗法的有效性与可靠性,为后续研发及监管申报提供了有力支持。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10